Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

February 23, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 74 min

Earnings Call Speaker Segments

Larry Keusch

executive
#1

Hello, everybody, and thanks for joining the Teleflex Inc. Fourth Quarter 2022 Earnings Conference Call. You can find the press release and the slides that go with this call on our site, teleflex.com. I want to point out that those watching the webcast may move the presentation slides forward themselves. Just keep following along with the presentation as we move through the call. Also, remember that a replay will be posted on our website. Anyone who wants to hear that replay should look at this morning's press release for the specifics. With us on today's call are Liam Kelly, Chairman, President and Chief Executive Officer, and Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom will give prepared remarks, after which we will take questions in a Q&A session. Before starting, I want to remind you that certain topics covered during the conference call will include forward-looking statements about future events, as described in the slides posted to the Investor Relations section of the Teleflex website; we caution you that these statements are, in fact, forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ materially include, but are not limited to, factors referenced in our press release today as well as our filings with the SEC included in our Form 10-K, which can be accessed on our website. During this conference call, you will hear management make statements regarding intra-quarter business performance. Management is providing this commentary to provide the investment community with additional insights concerning trends, and these disclosures may not occur in subsequent quarters. Having said that, I will now hand the call over to Liam for his remarks.

Liam Kelly

executive
#2

Thanks, Larry, and good morning to all of you. In Q4, Teleflex brought in revenues of $758 million, which was down 0.5% from the same period last year on a reported basis, while constant currency growth came in at 3.7%. Versus the equivalent quarter a year earlier, revenue tied to the manufacturing and supply transition agreement connected to our earlier divestiture of the Respiratory assets dragged growth down by 0.6% during the quarter, which means underlying constant currency growth was 4.3%. Adjusted earnings per share fell 2.2% compared with a year earlier, landing at $3.52; as we looked at the quarter, our Q4 constant currency revenue growth proved durable even with an unforeseen subcomponent supply chain problem in our Surgical business that created a headwind of roughly $3.5 million during the quarter. This solid quarter performance further illustrates the advantages of Teleflex's diversified portfolio, which was deliberately assembled to focus on caring for critically ill patients. Notably, our Interventional, Surgical and OEM product categories delivered double-digit constant currency revenue growth versus the prior year during Q4. On a positive note, we saw monthly growth improve sequentially, with December standing out as the quarter's strongest month as health care utilization keeps normalizing. Geographically speaking, Asia delivered robust results and remains a key growth engine for Teleflex. Raw material inflation and supply chain difficulties continued to weigh on the business in Q4. Tyvek remains in short supply and has mainly affected our Vascular and Interventional businesses. Now shifting to the full year 2022. After accounting for the Respiratory assets divestiture and one fewer shipping day, constant currency revenue growth reached 4.3% for 2022 as health care utilization got better over the course of the year and demand for Teleflex products picked up. Our high-growth revenue portfolio kept its momentum across most growth drivers. Even though UroLift constant currency revenue dropped 5% versus the prior year in 2022, the rest of the products in the high-growth portfolio kept posting healthy gains, with constant currency growth of about 14% for the year. Turning to durable core revenues; during 2022, durable core revenue rose roughly 5% on a constant currency basis compared with the same period a year earlier, driven by improvement in procedural volumes, strong global execution, new product introductions and positive price. Our other category, which covers our Respiratory and drainage catheter business plus revenue from the MSA we signed with Medline related to the sale of our respiratory business, was down just under 10% versus the prior year in 2022. Now let's take a deeper look at our Q4 revenue results. I'll start by reviewing our geographic segment revenues for Q4. All growth rates mentioned are on a constant currency basis unless stated otherwise. Americas revenues totaled $458 million, representing 1.7% growth versus a year earlier against a tough comp in the year ago period. Once you exclude the effect of the year-over-year decline in MSA sales, Americas revenue rose 2.7% in the quarter. Growth in our Interventional and Surgical segments reached double digits, though that was offset by decreases elsewhere in the business, among them Interventional Urology. In EMEA, revenue came to $147.8 million, up 1.4% compared with the prior year, and we keep seeing procedure volumes rise relative to last year; shifting attention now to Asia. There, revenue totaled $78.5 million, a 13.3% year-over-year increase. The region delivered strength broadly, with every geography delivering healthy growth in the fourth quarter. In China, growth neared 7% even with COVID-related interruptions late in the quarter. Now let's turn to a review of our fourth quarter revenues broken out by global product category. Remarks about fourth quarter growth by global product category will likewise be given on a constant currency basis. Beginning with Vascular Access. Revenue rose 0.5%, reaching $186.4 million. As expected, this quarter's results showed Vascular Access getting back to growth even with a difficult comparison in central venous catheters caused by fewer COVID patients in United States intensive care units versus the prior year. Even though we achieved sequential gains on back orders, the supply chain has not fully normalized. As we noted before, no part of the business faces more exposure to Tyvek packaging for our kits and trays than the vascular business. We expect Tyvek shortages to ease during the second half of 2023 as more supply for the industry becomes available. Looking longer term, we stay confident that our category leadership in central venous catheters and Midlands, together with our innovative coated PICC portfolio, keeps us positioned for reliable growth. Shifting to Interventional Access. Revenue reached $125.1 million, climbing 13.4% versus the prior year. Constant currency revenue growth improved sequentially throughout 2022 as procedure volumes recovered to where they stood before the pandemic. During the quarter, our diversified portfolio worked in our favor, with Balloon Pumps, OnControl, and MANTA each adding to growth. Now to Anesthesia. Revenue was $99.6 million, rising 2% from the prior year. Among our bigger franchises, products, hemostatic products, LMA single-use masks and endotracheal tubes each turned in strong fourth quarter performances, partly offset by regional anesthesia. Within our Surgical business, revenue came to $110.4 million, another solid result with 10.4% growth versus the prior year, despite the supply chain disruption described earlier that stemmed from a specific subcomponent supplier. Among our biggest product categories, skin stapling and our ligation portfolio added to growth. In other news, we completed the acquisition of Standard Bariatrics early in the fourth quarter, and Titan Stapler revenue accounted for a significant share of the Surgical business's year-over-year growth. As for Interventional Urology, revenue was $89.2 million, which was up 13.1% from the prior quarter and down 3.6% from the prior year. Interventional Urology kept facing pressure from fewer patient visits to urologists year-over-year along with staffing shortages. While the broader climate for elective BPH procedures has yet to normalize, the fourth quarter did show some encouraging signs. Third-party data suggests that total patient visits to urologists fell within the 3% to 4% range year-over-year during the fourth quarter, an improvement sequentially from the high single-digit year-over-year drop seen in the third quarter of 2022. OEM revenue rose 12% compared to the prior year, reaching $73.7 million, even with a very tough comparison against last year. Our backlog continues to be in a strong position, since customers see the wide range of things we do well, backed by competitive abilities, covering rapidly expanding areas such as thin walls, interventional microcatheters for reaching small vessels, and fine wire used in sensing and ablation technology. In the fourth quarter, other revenue fell 7.1% versus the same period a year earlier, landing at $73.6 million. Our expectation stays the same that every MSA revenue stream will come to an end once 2023 is over. That wraps up what I have to say regarding fourth quarter revenue results. Now moving to a few commercial and clinical matters. As I noted before, we closed on the purchase of Standard Bariatrics during the early portion of 2022's fourth quarter. Standard Bariatrics brought the Titan SGS Stapler to market for sleeve gastrectomy procedures used to address morbid obesity, and having this product join the Teleflex Surgical portfolio makes us very enthusiastic. Integration work is moving forward, and we are still meeting our targets. Notably, we have finished training the Teleflex sales team on the Titan Stapler, which lets us make the selling organization twice as large as what Standard Bariatrics had when operating independently. We also made an announcement not long ago that Teleflex received a group purchasing agreement from Premier covering the Titan Stapler.

Liam Kelly

executive
#3

This deal means surgeons who are part of Premier's network will be able to use the Titan Stapler, giving them access to this novel technology for gastric sleeve procedures. Now on to UroLift. During 2022, we hit our goal of switching the overwhelming majority of users over to UroLift 2, which frees up capacity for our sales team to devote more hours to market development work in 2023. We kept training new physicians through the fourth quarter and met our targets for the year. Notably, the count of doctors we trained in 2022 is still broadly in line with what we've seen historically, which signals ongoing interest in bringing UroLift into the BPH treatment paradigm. To help with onboarding new physicians for UroLift, we ran live BPH summit training sessions across the U.S., Australia and Japan in 2022. Our direct-to-consumer program continues to be a key investment and it hit the performance metrics we set in advance for 2022; we'll keep funding DTC efforts for UroLift, among them a refreshed television and digital campaign that debuted in February of 2023; let me now shift to an update on our international strategy for UroLift. We achieved substantial progress expanding UroLift geographically, entering a number of new markets in 2022, among them Japan and China. Beginning with Japan. Our launch execution was strong, with UroLift building sequential traction throughout 2022. Revenues came in above what we expected for the year, and we're seeing that momentum carry into 2023. Now to China. We began UroLift cases in the fourth quarter, as we had anticipated. Our launch activities will be methodical, following a playbook similar to the one that has worked well for us in Japan; in turn, 2023 will be spent training surgeons, building our footprint in key cities and keeping up engagement with the Chinese Urological Society to build acceptance. Now for our net base on the vascular business. The Vascular business unit keeps aligning its portfolio and clinical education offering with customer needs as they evolve. As of today, Teleflex is well positioned to act as a trusted partner for vascular access clinicians pursuing their goal of 0 catheter-related complications. We help standardize outcomes by delivering protection during and after vascular access procedures and by establishing a predictable insertion process throughout the hospital. This approach keeps solidifying our significant market share in CVCs and drives revenue growth through the highly successful launch of the CVC ErgoPack complete portfolio, which offers a complete vascular access insertion system designed to help clinicians comply with current guidelines and standards; we also keep prioritizing growth in the PICC and midline categories, with the most recent advancement being the launch of the new Arrow Pressure Injectable Midline portfolio in North America during the fourth quarter of 2022. The new offering is designed to help alleviate risk associated with line misidentification. Absent a simple, rapid way to tell midlines apart from PICCs, a drug could be given by mistake through a midline when it ought to go only through a central venous access device, which risks complications and interruptions to a patient's therapy; the launch remains in its early stage, yet customer interest has been substantial so far. We can expect further innovation along with PICC placement and positioning devices during 2023, as we keep pushing for growth and share gain within this segment. Now to the Interventional Access business. It is a pleasure to report that the Langston catheter relaunch moved through the fourth quarter, with the product available in the U.S., Canada, Australia and New Zealand. A distinctive diagnostic instrument, the Langston catheter lets clinicians establish how severe aortic stenosis is, which may lead to a TAVR procedure afterward. Our clinical and medical affairs team is working to reeducate the market about this product, including by way of a panel discussion at TCT and a webinar held in December. The Langston catheter keeps creating value for our customers, strengthens our engagement with clinicians in TAVR and shows our relevance in the structural heart space; over the years ahead, we expect additional product launches in our interventional business, among them complex catheters in the structural part market. Last, a few remarks on the 2023 outlook. During 2022 we saw health care utilization stabilize in an improving manner, and in 2023 we would anticipate a further sequential stabilization in health care utilization. In fact, most of the procedure markets we serve have now returned to or surpassed 2019 levels. On the other hand, certain disease states that are more deferrable mirror patient visits to physicians that are still under pre-pandemic levels, urology among them. As COVID becomes increasingly endemic and staffing shortage bottlenecks gradually loosen, we anticipate that patients will increasingly pursue medical interventions over the course of 2023. Now to the macro environment. 2022 brought its own operational challenges, among them inflation and supply chain disruptions. As we head into 2023, we are ready for a certain amount of continued volatility, though we would anticipate that incremental inflation will come in at levels below 2022 and that supply chain challenges will improve as the year goes on. Our global operations stay our focus, and we will seek out ways to grow more efficient as we navigate the macro environment. That brings my prepared remarks to a close. At this point I would like to hand the call to Tom for a more detailed review of our fourth quarter financial results. Tom?

Tom Powell

executive
#4

Thank you, Liam, and good morning. Since we've already gone over how the company performed on revenue, I'll start with margins. During the quarter, our adjusted gross margin came in at 60%, which represents a 120 basis point gain over the same period last year. That year-over-year improvement came from price, foreign exchange, and mix, though incremental inflation partially offset it. It's worth noting that our pricing approach kept gaining ground in the fourth quarter, which let us deliver year-over-year price improvement above 50 basis points for 2022. We — throughout the quarter, we kept observing better sea freight costs, consistent with what we had anticipated. On the other hand, raw material pressures and supply chain disruptions stayed high and still haven't returned to normal. Adjusted operating margin reached 27.9% in the fourth quarter. That 30 basis point year-over-year rise came about because of stronger gross margin and cost discipline on nonrevenue-generating expenses, partly offset by deleverage throughout our expense base resulting from lower revenue year-over-year; inflation within our expense base, including wages; and deliberate investment in the business for our growth drivers. Net interest expense came to $18.7 million in the fourth quarter, up from $11.8 million in the same period a year earlier. This year-over-year rise in net interest expense mirrors higher interest rates relative to last year and greater borrowings on our revolver to finance the purchase of Standard Bariatrics, partly offset by a decline in average debt outstanding. Our adjusted tax rate for the fourth quarter of 2022 stood at 13.6%, versus 13.8% in the prior year period. The year-over-year drop in our adjusted tax rate stems mainly from further enhancements and tax efficiencies in our global structure, partly offset by tax expense tied to the new provision of the U.S. tax law requiring capitalization of certain R&D expenses. At the bottom line, adjusted earnings per share for the fourth quarter was $3.52, which is 2.2% lower than the prior year. Now let's turn to a few balance sheet and cash flow highlights. Cash flow from operations for 2022 came in at $342.8 million, versus $652.1 million in the prior year period. That decline was mainly attributable to weaker operating results, larger tax payments, higher payroll and benefit-related payments, and unfavorable working capital changes caused by an increase in inventory purchases meant to sustain high customer service levels amid a stretch of elevated global supply chain volatility. Shifting to the balance sheet. Our financial position is still healthy. At the close of the fourth quarter, we held $292 million in cash, compared with $445.1 million at the end of 2021. The lower cash on hand reflects $240 million of payments on our senior credit facility and $73 million for the Standard Bariatrics acquisition. In addition, we drew $100 million under the senior credit facility for the Standard Bariatrics acquisition. Net leverage at quarter end was roughly 1.8x, still comfortably under our 4.5x covenant; now moving to our 2023 guidance update; we expect constant currency revenue growth of 4.75% to 6.25% for 2023. On the foreign exchange side, for 2023 we're looking at a roughly 0.5 point headwind. Once we factor that currency drag in, our reported revenue growth expectation for 2023 sits at 4.25% to 5.75%, which works out to a dollar range of $2.91 billion to $2.952 billion. For Standard Bariatrics, our revenue expectation remains unchanged, in the range of $30 million to $35 million. Now shifting to the middle of the income statement; for 2023 we're expecting gross margin of 59% to 59.5%. That guidance range captures the favorable effects of manufacturing efficiencies versus the prior year, along with product mix and price, which are largely offset by inflation. Even though sea freight costs moderated in the second half of 2022, consistent with what we had forecast, raw material inflation came in higher than we anticipated back at our May 2022 Analyst Meeting. And as we look at 2023, we've built in the assumption that macro volatility continues and that ongoing inflation across raw materials, labor and utilities will act as headwinds to gross margin this year. Shifting to operating margin. We're expecting a range of 26% to 26.75%. This guidance reflects the flow through of gross margin, head count and employee related expenses, investments to grow the business and the inclusion of Standard Bariatrics, partly offset by the favorable effect of restructuring. Now to items below the line. For 2023, we expect an adjusted tax rate in the 10.25% to 10.75% range. Net interest expense should come in at approximately $67 million for 2023. Most of the year-over-year increase in our net interest expense outlook comes from higher interest rates, partially offset by debt repayment. Now on to earnings. Our adjusted earnings per share guidance for 2023 is $13 to $13.60, representing a 0.5 point year-over-year decrease at the low end and a 4.1% increase at the high end. As you think about your models for 2023, foreign exchange will be a meaningful headwind to revenue during the first half and then increasingly shift to a tailwind in the second half of the year, assuming foreign exchange rates as of the beginning of 2023. That said, because of how foreign exchange flows through our inventory, EPS will face headwinds through the third quarter, and then it would become neutral in the fourth quarter. We'd also point out that while the number of shipping days in 2023 versus 2022 shows no year-over-year difference, there will be 5 extra shipping days in the first quarter and 5 less shipping days in the fourth quarter of this year. Historically, the benefit or headwind to our year-over-year GAAP revenue growth from a shipping day change is approximately 1% in a fiscal quarter. While we don't provide quarterly guidance, for your modeling purposes we would expect a constant currency revenue growth range in the first quarter of approximately 5.5% to 6.5% when excluding the benefit from 5 extra shipping days, of approximately 5%. To wrap up, I want to offer a few thoughts regarding our long-range plan. We continue to have confidence in the foundational pillars of the durable growth strategy we laid out at our Analyst Meeting in May 2022. Our plans spanning 2023 to 2025 remain rooted in specific drivers behind revenue growth, earnings per share growth, and margin expansion. Our focus stays on the long term as we work toward hitting our 2025 objectives, and we still see room to build greater scale, boost profitability, carry out a disciplined capital allocation approach, and generate robust cash flow for Teleflex. That said, the macro backdrop has proven extremely dynamic, and our business has faced several unexpected headwinds during the stretch since that May 2022 Analyst Meeting. To start, during the back half of 2022, inflation proved stubborn and came in above what we had forecast when we held our 2022 Analyst Meeting, especially when it came to raw material expenses and how those affected gross margins. Next, while we had expected procedure volumes for UroLift to improve sequentially across 2022, those headwinds lasted the whole year. Specifically, urologist patient visits declined compared with the prior year during 2022, and staffing shortfalls continued to constrain procedures, particularly within the office setting. Third, currency movements created a bigger drag than anticipated, since the dollar appreciated versus a wide range of currencies during the latter half of 2022. Rates of interest likewise climbed sharply over the second half of 2022, and they are projected to keep climbing throughout 2023. While we have not rebuilt the whole LRP that we gave in May 2022, we have revised our assumptions around inflation, foreign exchange, and interest rates. Beyond that, we now assume a 3-year CAGR within the 8% to 9% band for UroLift revenues worldwide. And last, given that we bought Standard Bariatrics during the early part of the fourth quarter of 2022, we have folded that business into the long-range plan. We still regard the LRP targets we shared at the 2022 Analyst Meeting as the vision for Teleflex in 2025. Using 2022 as the base year while factoring in these updates, we now expect to land at the low end of the ranges for 2023 to 2025 total revenue CAGR and margin expansion. Within the high-growth portfolio, which accounted for a little more than 25% of revenues in 2022, we anticipate roughly 12% to 13% CAGR across the LRP. Within the durable core, which makes up slightly over 60% of revenues in 2022, we anticipate growth of approximately a 5% CAGR. As for the rest of total revenue, which we call the other category, we anticipate a negative 6% to 7% CAGR from the LRP. That brings my prepared remarks to a close. I will now hand things back to Liam for some closing commentary.

Liam Kelly

executive
#5

Thanks, Tom. To wrap up, I want to emphasize 3 main points regarding Q4 of 2022 and what we expect for 2023. First, the results we posted in the fourth quarter were strong, and they came about because end markets improved across most of the businesses we operate. Second, when it comes to 2023, we feel good about what lies ahead. That view takes into account how the Teleflex portfolio is diversified, achieved by bringing together our growth drivers with the steadiness of durable core revenues. What matters greatly is that we keep directing investment toward the drivers of future growth so that long-term value creation is strengthened. Third, our attention is set on meeting the goals we've laid out for 2025. We take a balanced path toward top line growth, putting money into our growth drivers while also making the durable core perform as well as it can. We identify chances to push margin expansion via mix shift, restructuring and price. And last, discipline will guide how we allocate capital, centering on carrying out our M&A strategy. With that, my prepared remarks are done. I'd now like to hand the call back to the operator so we can move into Q&A.

Cecilia Furlong

analyst
#6

Liam, I'd like to begin with the '23 guidance, and could you take us through how we ought to think about contributions from the durable core and the high-growth assets in UroLift, relative to the updated LRP and those CAGRs? And specifically regarding UroLift and that 8% to 9% CAGR, what's your thinking on the cadence across the next 3 years?

Liam Kelly

executive
#7

Yes. Cecilia, thanks for asking. I'll begin with the overarching revenue guidance for '23, which sits at 4.75% to 6.25%, with a midpoint of 5.5%. That's an improvement versus 2022, when the underlying growth rate was 4.3%. And when it comes to cadence during the year, you heard it in Tom's prepared comments, of course: quarter 1 will come in at 5.5% to 6.5%, with a midpoint of 6%. So clearly, we're seeing core revenue improve right out of the gate. As a company, we keep concentrating our efforts on high growth and durable core, which addresses the other part of what you asked; but guiding these buckets as they contribute to Teleflex's overall growth rate is simply the natural evolution for us. Our assumption in the 2023 guidance, Cecilia, is that high growth will rise 8% to 11%; durable core will rise 4.5% to 5.5%; and the other bucket will be flat to declining in 2023. As you're aware, we're an incredibly transparent company. And although we won't guide specifically to UroLift, we'll report Interventional Urology revenues each quarter, consistent with all our other product categories. The exception this year will be Standard Bariatrics and the Titan Stapler, since we've guided the full year at $30 million to $35 million. That aligns with our past guidance principles of providing guidance to an acquisition within the first year. Naturally, for UroLift, we'd anticipate an improving environment in 2023, and that would continue into '24 and '25, Cecilia.

Cecilia Furlong

analyst
#8

Excellent; and next, if I may ask a second question regarding gross margin, specifically the guidance you issued for '23, could you detail both what you anticipate from the ongoing inflation advantage tied to pricing? And also the effect that converting to UroLift 2 is having on gross margin, together with Standard Bariatrics?

Liam Kelly

executive
#9

All right. I will handle only the UroLift 2 conversion piece, and Tom will address the remaining margin subjects, Cecilia. As for UroLift 2, at this point we've largely completed converting the U.S. market to UroLift 2, and Tom will walk through your other gross margin questions.

Tom Powell

executive
#10

All right. So when we look at 2023, the target we're giving is 59 to 59.5, which works out to roughly 5 basis points at the midpoint. And during 2023, we anticipate achieving significant margin accretion driven by a blend of mix, price, manufacturing cost improvement programs, and our footprint restructuring programs. That said, as we discussed back in 2022, we still anticipate that inflation will mostly cancel out those gains. On top of that, we foresee a slight gross margin headwind coming from foreign exchange. If we break down the drivers behind that accretion, the biggest one is the cost improvement programs, which represent around 40% of the positives, followed by mix, price, and the footprint, each contributing roughly 20% of the increase. Then, when we examine what's working against that, it's mainly inflation, which makes up 80% of the offset. And as I mentioned, a small portion comes from foreign exchange too, along with some miscellaneous other items. So really, this is a story of genuinely strong underlying margin expansion opportunities. Like we said, we continue to feel quite good about the long-term prospects. Even so, inflation is making its presence felt and is mostly canceling out those solid gains in the underlying business.

Michael Sarcone

analyst
#11

This is Mike Sarcone, filling in for Matt today. So, only 2 follow-ups regarding what Cecilia asked. First, about that UroLift growth CAGR of 8% to 9% across the coming 3 years. Any chance you could break down how you see U.S. growth versus OUS growth?

Liam Kelly

executive
#12

Yes; so what I'll tell you is that for the UroLift guidance within the LRP over the years ahead, our assumption is that UroLift grows 12% to 13%. So 2 remarks on that; we — the high growth will be 12%, 13%. And inside that, UroLift grows 8% to 9%. So a few remarks on that. First, our international assumptions haven't changed at all. We remain confident about rolling out the product in Japan. As we mentioned in our prepared remarks, we've started in China. Additional geographies are coming on board, like Brazil, Taiwan, India, France, Italy, Spain and, in the end, Germany as you move through the LRP cadence. I'd also add that 2022 unfolded somewhat differently than we expected in the U.S. regarding procedural recovery — much slower than we had expected because of patient flow and staffing shortages. And I think, at a high level, if you look at Teleflex as a company inside that high-growth bucket, in 2022, it's 25% of our company growing at 12% to 13%, By 2025, it will be 1/3 of our company still growing at that 12%, 13%. And I think this, together with our growth within UroLift, will position Teleflex as for attractive long-term durable growth as a company.

Michael Sarcone

analyst
#13

Understood, that's quite useful. If I could just ask one more thing regarding gross margins in 2023 — could you assist us in thinking through the quarterly pattern across the year, and how gross margin ought to move?

Tom Powell

executive
#14

Sure. I would note that foreign exchange and other items bring both positives and negatives. What you ought to anticipate, though, is a fairly steady gross margin across the first 3 quarters, followed by margin expansion, or additional expansion, in the fourth quarter, driven by expectations of greater volume and a more favorable mix.

Shagun Singh Chadha

analyst
#15

Thanks. So regarding UroLift, the LRP guidance sits at roughly 8% to 9%. Would mid-single-digit be a fair estimate for the current year? Also, I'd like to hear your perspective on why you're confident patients will come back. Is there a backlog you can draw on? It's encouraging that physicians keep training; then for my second question about EPS, the range is quite wide; so what drives reaching the top end rather than the bottom? And which factors cause the biggest swings?

Liam Kelly

executive
#16

Alright. Shagun, thanks for asking. Tom will address the EPS range shortly, but I'll start with UroLift. Clearly, we're confident about the 8% to 9% for UroLift in our LRP. Our belief is that it will keep improving throughout the LRP. As I mentioned before, our assumptions for international markets remain unchanged, and we still expect those international markets to perform well. We feel positive about worldwide growth for the UroLift franchise given all of that and given the better environment we expect, as we noted in our prepared remarks. That underpins our confidence in LRP growth of 8% to 9% CAGR from now through 2025; regarding your question about patients coming back, I think 2 factors need consideration: patient returns and staffing shortages. We observed — during the fourth quarter, there was a 13% sequential gain from Q3 to Q4; across every one of our businesses, we saw gains as the fourth quarter progressed, as we stated — in our prepared remarks. The same held for UroLift as that fourth quarter progressed. Gains appeared as you moved through the 3 months of the fourth quarter. I was actually — and in the end, we exceeded the UroLift — our UroLift expectations by more than $3 million during the fourth quarter, which is the first instance we've achieved that in a couple of quarters now, which provides some encouragement going forward. I was traveling last week, I spent several days with our urology sales team on UroLift and meeting customers. Although we're noticing some gains in hospital staffing levels, we still aren't seeing that in the ASC and in the office setting. I do expect that, that will get better as we move through this year 2023; and I also think patient flow will start coming back to the office. We'll support that by continuing to train urologists. And we trained approximately 400 urologists last year. Everything within our control, we're handling, I think, really, really well. Our DTC campaign is going to keep going, and we've just rolled out a fresh advertisement. Also, keep in mind that BPH is not disappearing. There are still 12 million men who have BPH; treatment can be put off, yet the condition remains. We continue to be the top-tier offering for treating BPH. In practice, we hold the leading position in the market for BPH treatment, and that's what gives us assurance about the CAGR for UroLift across the LRP.

Tom Powell

executive
#17

Now, regarding earnings per share, we're looking at a range around $0.60, and that's just under 5% from the high end to the low end. The things that could get us to the upper end would be a better product mix in our sales throughout the year, along with inflation holding steady at a particular level. If I had to describe what the real swing factor is here, I'd say the biggest ones are likely foreign exchange rates — which have shown themselves to be quite volatile over the last year — and simply where inflation ends up going. So those are probably the 2 largest swing factors in the guidance.

Mike Polark

analyst
#18

Two things on the refreshed LRP remarks — revenue first, then margin. Regarding revenue, I picked up the low end; previously the CAGR was framed at 6% to 7% across the whole company. So let's say 6%. What I want to know is whether that revision bakes in any further deals that haven't been announced. Or does it reflect just the base plus Standard Bariatrics, with no contribution from unannounced M&A?

Liam Kelly

executive
#19

Mike, I appreciate the question. You've got it exactly right. What we have is the base, together with the updated UroLift CAGR and Standard Bariatrics folded in; that's the sole adjustment we made. Your understanding is correct.

Mike Polark

analyst
#20

Alright. Turning to margin in light of the revised LRP remarks — just to make sure we're aligned — the bottom of the earlier targets for gross and operating margin growth, starting from '22. Gross margin in '22 was 59.2. Adding 250 basis points puts me just under 62% for 2025. Then for operating margin, 27% plus 200 bps gives 29% in 2025. Is that math right on my end?

Liam Kelly

executive
#21

That's right.

Jayson Bedford

analyst
#22

I'd like to ask about operating margin — Q4 came in solid, yet the guidance for '23 op margin looks somewhat weaker, and the pressure appears concentrated entirely on the operating line, OpEx. That points to a fairly steep increase in OpEx, and my assumption is that restructuring is partly helping that line. What I'm really trying to get at is: where is the reinvestment happening, and what portion of it would you call structural, driven by inflation, or discretionary?

Tom Powell

executive
#23

To pick up on what you said, when we examine the op margin for 2023, the starting point is that because of inflationary pressure plus foreign exchange, the gross margin lift we receive is smaller than what we'd normally see. So the gross margin tailwind we begin with is limited. Then, looking at OpEx, a few items come to mind that I'd describe as structural, meaning head count-related expenses we are adding back during 2023 that weren't present in 2022. Variable compensation landed below target, and we had a number of open positions — quite a few sat unfilled for some time because of the tight labor market — and now those roles have been filled, plus we're bringing variable comp back up to 100%. That produces a fairly significant structural shift. As for growth investments, we have ongoing spending behind our high-growth drivers. One example is expansion into international markets, along with continuing to develop the capabilities of our systems and other areas during 2023. Restructuring does deliver a benefit, by the way. Some of it lands in gross margin, some in OpEx, with a portion in 2023 and the remainder in 2024 — roughly 2/3 of that restructuring will help 2023. So on the whole, I'd say the largest effect is simply the structural return of costs into OpEx that weren't present in 2022. That's partly why 2022 benefited from a higher margin, since those costs weren't part of the cost structure.

Jayson Bedford

analyst
#24

How much dilution should we expect from Standard Bariatrics in 2023?

Liam Kelly

executive
#25

As we've said previously, Jayson, that figure comes to $0.10. So it was...

Tom Powell

executive
#26

Somewhere between $0.10 and $0.15.

Liam Kelly

executive
#27

For the current year, that figure ranges from $0.10 to $0.15, while during the fourth — during the prior year, it came in at $0.10.

Larry Biegelsen

analyst
#28

I have one about '23 and one about the LRP. Regarding 2023, Tom, could you walk me through the calculation? The midpoint for Q1 guidance is 6% on a day-adjusted basis, which I believe is constant currency. That seems a bit under what's expected for the remaining months. Why is that — why is the growth rate for Q2 through Q4 going to be smaller than what Q1 shows, assuming my math is right?

Liam Kelly

executive
#29

Larry, if it's alright with you, I'll handle that question rather than Tom. The main factor is really the year-over-year comparison. As you may remember, Omicron hit last year, and it had a modest effect on certain procedures we were performing. On top of that, we're anticipating a strong, solid showing in Q1 across the overseas markets and in OEMs, and that's simply due to how the prior-year period played out. That's the reason things are somewhat weighted toward the front end, Larry. From what I've seen in my career, most investors would rather have revenue plans weighted toward the front end than toward the back end. So I believe starting off quite strongly with 6% growth, given that our full year guidance midpoint sits at 5.5%, ought to be viewed as a favorable sign by the investment community.

Larry Biegelsen

analyst
#30

Okay, yes. So I agree with that on the front-end loaded comment, Liam. And then on the LRP, I guess maybe 2 parts. One, if I'm just thinking about the math right, the 5% — I think the midpoint for revenue, it's about 5% organic this year in '23, if I'm thinking about that right but 6% now for the LRP. So it implies an acceleration in '24 and '25, if I'm thinking about that right. And on the margins, to follow up on the earlier question, people are going to now look at this operating margin, for example, at 26.3 at the midpoint for '23 and approximately 29% goal in 2025. That's a pretty big step-up of about 300 basis points. So basically, what gives you the confidence in both of those, if I'm thinking about the revenue acceleration in '24 and '25 correctly here? And then on the margins, basically 150 basis points a year in '24 and '25. What gives you that confidence?

Liam Kelly

executive
#31

Okay. So I'll cover the LRP, and Tom will cover the margin question; but I know what Tom's answer is, it's going to be really focused on inflation, Larry, which should be no surprise to anybody, given the environment that we're in. But let me cover the revenue; it's all constant currency. So what I'm going to talk about is constant currency. So the first year of the LRP will be 5.5%; we're at the — we're guiding to the low end of our LRP, which is 6%. So you are correct. There is a modest uptick in revenue as you go from this year 2023 and to '24 and '25. And why is that? One of the main reasons for that is the improving macro environment that we expect to see beginning as we go through '23 and continuing into '24 and '25. The second factor that will help that is the international expansion of some of our high-growth portfolio, not just UroLift, but also the international expansion of PICCs, the international expansion of the intraosseous portfolio, the international expansion of the hemostatic products that will bring accelerated growth in the latter half of the LRP. And we feel pretty confident in that. It's not a managed step-up. We're going from 5.5% to a 6% CAGR over the horizon of the LRP. And I think the other comment that I will make that nobody has picked up on so far in their questioning is durable core was 4% to 5%. While we've been micro-focused on one element of Teleflex, the durable core has been improving all this time. And now the durable core for the LRP is now 5% at the upper end of the original guide of 4% to 5% through excellent execution by the businesses globally; and the margins on a high portion of that durable core are fairly substantive and helpful to Teleflex. Also, the total addressable market worldwide for the high-growth segment is $14 billion, and our penetration stands at just 5%. So there's considerable room for us to keep expanding within it. That said, I'll hand it over to Tom to respond to your margin inquiry, Larry, and I appreciate the questions.

Tom Powell

executive
#32

Okay, Larry. The main reason operating margin is going to widen is mostly because of gross margin. When you look at the pieces, we anticipate ongoing margin improvement from both mix and price. On top of that, there's our MSA with Medline, which wraps up at the close of 2023, and because of it we gain nearly a full point of margin. Then the third piece: normally our operations have sufficient productivity to exceed inflation by more than enough. That didn't happen during 2022, and it isn't happening during 2023. We do anticipate seeing some easing on inflation as we move into '24 and '25. Because of that, productivity from operations turns accretive to gross margin again, rather than dilutive the way it was in '22 and '23. Those, then, are essentially the primary forces behind gross margin. We also anticipate some leverage in operating margin stemming from rising revenues, which lets us leverage that cost structure. So if I were to list the main elements, those 4 points are what I'd point to.

Mike Matson

analyst
#33

I'd like to ask about pricing. My understanding is that you mentioned more than 50 basis points, and I believe that figure applied to the whole of 2022. What sort of assumption have you built into the guidance for '23? Does it stay around that same level? Might it potentially be even greater?

Liam Kelly

executive
#34

When 2022 started, our expectation was 50 basis points of positive pricing, and we went past that target during 2022, Mike. As a result, we finished well ahead of those 50 basis points. Once more, our expectation is to be above 50 basis points and to achieve no less than 50 basis points of pricing in the current year. And we have a route to get there; some carryover exists from the earlier year, plus we have further pricing opportunities, a number of which have already been put into action.

Mike Matson

analyst
#35

All right, I understand. And I believe Tom mentioned some restructuring when he discussed the margin, so does that refer to programs already in place? Or is something new being planned there?

Tom Powell

executive
#36

Those are programs already in place. We have several footprint programs that are still being finalized and will be mostly finished by 2025. And then in the fourth quarter of 2022, we launched a new program that will be done by 2024. So all of what I discussed consists of known, existing programs that, honestly, we are managing to expectations.

Matthew O'Brien

analyst
#37

So Liam, when I consider UroLift and that fresh 8% to 9% CAGR across the LRP, my sense is that works out to roughly $90 million to $100 million in added revenue during that period by '25. If my memory serves, Japan and China were expected to contribute quite substantially in those later years — perhaps half of that $90 million to $100 million, or possibly somewhat more. That would suggest only a rather modest gain on the domestic side. First, is my understanding correct? And second, how cautious is that projection? Does it really make sense to be putting this DTC spending in place if you don't believe the U.S. business can genuinely pick up speed across the coming several years?

Liam Kelly

executive
#38

So Matt, your general arithmetic is pretty sound when it comes to UroLift's expansion across that 3-year window. My view is we remain dependent on the U.S. to generate most of that growth, simply because the markets abroad aren't large enough. Obviously, when it comes to overseas and international, we're pleased with our progress. And once we reach the close of 2025, it will represent a larger share of revenue. And naturally, off a smaller base, the percentage growth will look considerably stronger. We've performed very well in Japan. We're going to perform very well in China, Taiwan, India, France, Spain, Italy, Germany, Brazil and so forth, but those markets simply aren't large enough to sustain the growth needed to reach that CAGR of 8% to 11%. To address the other part of your question, I believe the DTC does make sense. Looking back at 2022 according to what we expected, impressions rose by 27%. Responses climbed at a double — a very robust double-digit rate. So we view that as an encouraging signal. And whenever I speak with urologists — and this held true last week while I was traveling — patients are approaching them and requesting UroLift because of the ad campaigns they encounter; so I think we'll keep the DTC campaign going; and we believe 8% to 11% is quite attainable for our company.

Matthew O'Brien

analyst
#39

All right. And regarding the high-growth portfolio too, it's dipping somewhat from — I believe the prior figure was 14% to 15%, and at present it stands at 12% to 13%, which still suggests that the remainder of the portfolio beyond UL is performing strongly. Could you discuss a few of those elements — what you're observing with MANTA, EZ-IO, PICCs, and so on — that give you the assurance to reaffirm the strength of that portion of the business across the coming several years?

Liam Kelly

executive
#40

Sure. The high growth is performing very well indeed. During the fourth quarter, it expanded by roughly 14%. For the entire year, it expanded by roughly 14% excluding what UroLift contributed. So clearly, certain pieces inside the high growth exceed the average we anticipate, while other pieces of the high growth will come in a bit under it. Clearly, at this point Titan, which originates from Standard Bariatrics, is going to be the quickest expanding. After that comes MANTA, which is going to expand beyond the average. So our confidence in the high-growth portfolio is very strong. Our confidence in our ability to achieve the high growth of 12% to 13% throughout the LRP is very strong, and our confidence in our ability to achieve 8% to 11% from the high growth during 2023 is very strong. And every other part of the high growth except one has performed exactly in line with, or even beyond, what we expected throughout all of 2022. And as you're aware, Matt, nothing beats momentum when you're entering '23, '24 and '25 while you keep developing that; and I realize we discuss international expansion with UroLift often, yet the same holds true for the remainder of the high growth. There's international expansion plus domestic sales growth as we reach into that market. And what's encouraging is, as I mentioned before, this entire high growth is expanding into an enormous market TAM, where our penetration is quite low, yet there are considerable opportunities for growth.

Anthony Petrone

analyst
#41

Perhaps regarding the LRP and Standard Bariatrics, just to clarify things a little when it comes to the top line contribution — my assumption is that it rolls into organic at some point later in this year or in early next year. So maybe you could address what Standard Bariatrics contributes within the LRP, and whether that can actually be margin accretive by the time the LRP ends? And I have a few follow-ups after that.

Liam Kelly

executive
#42

Let me take the final part of your question first. Yes, by the end of the LRP it will be margin-accretive. As we exit 2024, we expect it to turn margin-accretive. What you should expect from Standard Bariatrics is a delivery of between $30 million and $35 million this year, as we stated in our prepared remarks. And then, as we said previously, from an organic perspective it should add approximately 50 basis points of growth to Teleflex year-over-year thereafter; so that's what you should expect from Standard Bariatrics. Rough math, it should be around $60 million by the end of 2025.

Anthony Petrone

analyst
#43

Then a fast second question, 2, which I'll ask now before rejoining the queue. First, regarding UroLift, as we consider it across 2025. Clearly, patient behavior has shifted somewhat. When do you figure matters will more or less settle down? Is there a route to settling down, perhaps by the close of this year or at the start of the next one? I mean U.S. patient behavior; and then perhaps your latest thinking on the M&A picture, what degree of talks is Teleflex involved in, and maybe your broad perspective on M&A?

Liam Kelly

executive
#44

Yes. Of course, Anthony. So my expectation is that the broader situation for urology patients and staffing keeps getting better throughout 2023. Exactly when it will be 100% normal, Anthony, honestly, is hard for me to nail down at this moment. Yet I do expect continued improvement; and why do I believe that? Hospital staffing numbers started getting better in Q4. My expectation is that carries on into Q1 this year. And when hospital staffing numbers begin getting better, that will eventually lead to improvement in ASCs and, after that, ultimately in offices; and I think patient flow, as I mentioned before, there remain 12 million men who suffer from BPH. If you enter a urologist's office, and 100 men are in the urology waiting room, approximately 40 of them are there due to BPH. So it remains the #1 reason a man visits the urologist. So the market's size is a major factor behind my conviction that it will get back to normal as we move through the LRP at some point. As for M&A, obviously, we possess the most crucial thing required. Our balance sheet is very strong. On M&A, at the close of the fourth quarter, we're about 1.75x levered. We are busy out there reviewing opportunities. We have many lines in the water. We're fishing hard, Anthony. It's very hard for me to predict, and we're going to get a fish on the hook and into the boat; but targets exist that interest us. Targets exist that we are actively chasing. And we do believe we're an appealing acquirer and there are assets we feel would be a great fit within the Teleflex family.

Craig Bijou

analyst
#45

First, I'd like to begin with UroLift. I wanted to check something — I'm aware Japan came in above expectations. Did Japan account for that figure in the quarter, the 89 against the 86 your guidance had suggested? Or, if you don't mind, could you speak to what produced the beat of a few million? Was it from the U.S., or from outside the country?

Liam Kelly

executive
#46

Improvement showed up on both sides of the Atlantic, Craig. I keep returning to this: at this point, the markets outside the U.S. simply aren't big enough to shoulder the whole UroLift growth story. And without the U.S. contributing a sizable share, we couldn't have exceeded the target by $3.3 million. Still, as I mentioned before, I take encouragement from our overseas expansion efforts. Japan has performed remarkably well. Our initial cases in China are done; rollout is beginning in India and additional geographies. I won't list them all once more, but that rollout leaves us feeling optimistic.

Craig Bijou

analyst
#47

Understood. Then regarding what you said about the durable core — I appreciate that, and how it has sort of climbed when it comes to LRP growth. Perhaps — I mean, which products and categories are primarily fueling that, and which ones do you expect to fuel that LRP growth over the coming years?

Liam Kelly

executive
#48

Yeah. When I consider where we're seeing an uptick within a better environment, the first thing you need to grasp is that back in 2022, supply chain problems were plentiful; we ran short on Tyvek, ran short on basic components, and things like that. So some of the initial gains you'll witness will come from that. So an uptick in our Vascular business ought to be visible. As you move through 2023 and past it, Vascular expanded across the whole year by roughly 1% constant currency. For that business, typical growth sits in the mid-single digits. I'd also say that with Interventional Access, we have a wonderful set of new offerings rolling out, and that represents the late blood of that business; and we'd expect Interventional Access to keep speeding up. One of our — I suppose, beyond the durable core, one of our assets that gets too little credit is our OEM business. A couple of years back we acquired a company named HPC; it makes thin-walled catheters. That, along with the remainder of the OEM business, has kept expanding in the high single, low double digits, from a business that in the past typically grew at about 3% or 4%. So I expect that OEM will keep thriving, will keep speeding up its growth throughout the LRP and be a genuine contributor. And don't overlook that it's accretive to our operating margin and will fuel that. And clearly, APAC is a crucial growth franchise for us. We have plenty of products we're introducing into the APAC region that we think will do very well there. So those are a few of the key areas that I think will keep growing; and as I mentioned before, as we move through the LRP, we'd expect that Interventional Urology would likewise get better as we move through the LRP.

George Sellers

analyst
#49

I'll keep this brief with just one question. Can you share some insight into private market valuations and where they've been heading lately? And how assured are you that you might be able to put some capital to work in the near future?

Liam Kelly

executive
#50

George, as you're aware, it takes 2 people to make a marriage work. So we're ready to be either the groom or the bride, however you'd like to characterize us; the real challenge is locating the counterparty. What I can say is that valuations have eased a bit compared to the exuberant period of 2021. And top-tier assets remain — not cheap, but that's precisely what makes them top-tier assets, and those are the ones we're pursuing. That said, you can — we're going to stay disciplined, George, and our investors should count on us staying disciplined. We'll seek out assets that boost our top line growth. We'll seek out assets that lift our gross margins. We'll seek out assets that will enhance our op margins and earnings fairly rapidly once we've acquired them. We will — we hold ourselves to strict standards on return on capital and exceeding our internal cost of capital by at least year 5; we've consistently managed to achieve that by year 4. But the bar will stay where it is for Teleflex when it comes to identifying strong assets, welcoming them into the fold and incorporating them into Teleflex and, clearly, assets that stand out in the marketplace within segments expanding more rapidly than the core segments inside Teleflex.

Matthew Mishan

analyst
#51

I just want a fast clarification from Liam, and after that I have a follow-up question for Tom. Regarding the bottom end of that 6% to 7% range spanning '22 through '25, is the inorganic addition from Standard Bariatrics during 2023 factored into that figure?

Liam Kelly

executive
#52

It is. Like we mentioned during our prepared remarks, and like I've noted on a couple of occasions now, what we're doing with these adjustments is revising the high-growth bucket along with the UroLift piece inside that high-growth bucket, and Standard Bariatrics is being added in. So that covers it. You've got that right.

Matthew Mishan

analyst
#53

All right. Then for Tom, regarding the tax rate, 10.25% to 10.75% for 2023 is quite low, particularly when you stack it up against historical norms. What is causing that in 2023? And how should we view whether that tax rate can hold up as we move into the next couple of years?

Tom Powell

executive
#54

Well, I'd say when you look at 2023, two things are driving the tax rate. The first is the shift in tax law involving capitalization of R&D expenses, which will begin giving us some capacity to amortize in 2023, so the expense impact is smaller because of that; and the second thing driving it is the IT consolidation projects, or consolidation projects, that we've taken on will start delivering a bigger benefit in 2023. And those benefits are going to keep going throughout the LRP time frame. So you ought to view the rate as something that can be sustained. I'd note there's one caveat, which is that the EU right now is evaluating a minimum tax. Should that turn into legislation, it might hurt our tax rate.

Liam Kelly

executive
#55

And Matt, I just want to...

Tom Powell

executive
#56

And I ought to mention that this is being considered for 2024, so there will be no effect on 2023.

Liam Kelly

executive
#57

My apologies, Tom. Right. And Matt, I'd like to return to what you asked about Standard Bariatrics. Between pro forma and Standard Bariatrics as is, the gap isn't all that large, since this product has only just reached the market and Teleflex has fueled the growth after we trained our sales team; we've therefore doubled that sales team. So it isn't all that large, the gap either way, Matt — that's what I'd tell you.

Larry Keusch

executive
#58

Thank you, Emily, and thanks as well to each of you who has come onto today's call. That brings the Teleflex Incorporated Fourth Quarter 2022 Earnings Conference Call to a close.

Operator

operator
#59

I appreciate all of you being here with us at this time. That brings today's conference call to a close. We're grateful that you took part. At this point, please hang up your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.